Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome

Background: Cortical areas showing abnormal glucose metabolism and [11C]flumazenil (FMZ) binding are commonly seen on PET scans of patients with intractable partial epilepsy, but it is unclear whether these must be totally resected to achieve seizure control. Objective: To analyze whether the extent of cortex showing 2-deoxy-2-[18F]fluoro-d-glucose (FDG) or FMZ PET abnormalities correlates with the outcome of resective epilepsy surgery. Methods: Cortical FDG and FMZ PET abnormalities in 15 young patients (mean age, 12.2 ± 7.0 years) with intractable partial epilepsy of neocortical origin were marked as regions with abnormal asymmetry using an objective semiautomated software package. These marked regions were then projected and measured on the brain surface reconstructed from the coregistered high-resolution MRI. Following cortical resection, the size of nonresected cortex with preoperative PET abnormalities was also measured (calculated separately for marked areas in the lobe of seizure onset as defined by long-term video EEG monitoring, and in remote cortical areas). Extent of preoperative PET abnormalities and postoperative nonresected cortex abnormalities on PET were correlated with outcome scores. Results: Large preoperative FMZ PET abnormalities were associated with poor outcome (r = 0.57; p = 0.025). Larger areas of nonresected cortex with preoperative FMZ PET abnormalities in the lobe of seizure onset were also associated with worse outcome in the whole group (r = 0.66; p = 0.007) as well as in patients with extratemporal resection (r = 0.73; p = 0.007), and in those with no lesion on MRI (r = 0.60; p = 0.049). Patients with seizure-free outcome had significantly smaller nonresected cortex with preoperative FMZ PET abnormalities than those who continued to have seizures (p = 0.022). No significant correlations between nonresected FDG PET abnormalities and surgical outcome were found. Conclusions: Extensive cortical abnormalities on FMZ PET predict poor outcome in neocortical epilepsy surgery. Resection of FMZ abnormalities in the lobe of seizure onset is associated with excellent outcome even in the absence of a structural lesion. In contrast, although FDG PET abnormalities regionalized the epileptogenic area, their size was not related to the extent of epileptogenic tissue to be removed.

[1]  M. Richardson,et al.  Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An 11C‐flumazenil PET study , 1996, Annals of neurology.

[2]  B. Gulyás,et al.  Regional increases in [11 C]flumazenil binding after epilepsy surgery , 1998, Acta neurologica Scandinavica.

[3]  J. Engel,et al.  Surgery for seizures. , 1996, The New England journal of medicine.

[4]  Ivanka Savic,et al.  [11C]Flumazenil Positron Emission Tomography Visualizes Frontal Epileptogenic Regions , 1995, Epilepsia.

[5]  R. Kessler,et al.  Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. , 1996, Investigative radiology.

[6]  O Muzik,et al.  Objective method for localization of cortical asymmetries using positron emission tomography to aid surgical resection of epileptic foci. , 1998, Computer aided surgery : official journal of the International Society for Computer Aided Surgery.

[7]  O Muzik,et al.  Intracranial EEG versus flumazenil and glucose PET in children with extratemporal lobe epilepsy , 2000, Neurology.

[8]  F. Gilles,et al.  Usefulness of [18F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. , 1996, Pediatric neurology.

[9]  P. V. Ness Surgical outcome for neocortical (extrahippocampal) focal epilepsy , 1991 .

[10]  Otto Muzik,et al.  Identification of Frontal Lobe Epileptic Foci in Children Using Positron Emission Tomography , 1997, Epilepsia.

[11]  I Savic,et al.  Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[12]  Conrad V. Kufta,et al.  FDG‐Positron Emission Tomography and Invasive EEG: Seizure Focus Detection and Surgical Outcome , 1997, Epilepsia.

[13]  G. Franck,et al.  Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy? , 1997, Journal of neurology, neurosurgery, and psychiatry.

[14]  M. Sperling,et al.  The syndrome of frontal lobe epilepsy , 1995, Neurology.

[15]  O Muzik,et al.  Electroclinical correlates of flumazenil and fluorodeoxyglucose PET abnormalities in lesional epilepsy , 2000, Neurology.

[16]  A. Alavi,et al.  Predictors of outcome after anterior temporal lobectomy , 1994, Neurology.

[17]  M. Duchowny,et al.  Predictors of outcome in pediatric epilepsy surgery , 2000, Neurology.

[18]  R. North,et al.  Surgical treatment of focal epilepsy in children: results in 37 patients. , 1997, Pediatric neurosurgery.

[19]  Otto Muzik,et al.  Is epileptogenic cortex truly hypometabolic on interictal positron emission tomography? , 2000, Annals of neurology.

[20]  O. Muzik,et al.  Glucose and [11C]flumazenil positron emission tomography abnormalities of thalamic nuclei in temporal lobe epilepsy , 1999, Neurology.

[21]  O Muzik,et al.  [11C]flumazenil PET: activity images versus parametric images for the detection of neocortical epileptic foci. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  Jerome Engel,et al.  Outcome with respect to epileptic seizures. , 1993 .

[23]  Juan Bulacio,et al.  Seizure outcome after epilepsy surgery in children and adolescents , 1998, Annals of neurology.

[24]  M. Mandelkern,et al.  Neuroimaging in Temporal Lobe Epilepsy: Test Sensitivity and Relationships to Pathology and Postoperative Outcome , 1992, Epilepsia.

[25]  J C Froment,et al.  Clinical utility of flumazenil-PET versus [18F]fluorodeoxyglucose-PET and MRI in refractory partial epilepsy. A prospective study in 100 patients. , 1998, Brain : a journal of neurology.

[26]  H. Lüders,et al.  Outcome of temporal lobe epilepsy surgery predicted by statistical parametric PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  D J Brooks,et al.  11C-flumazenil PET in neocortical epilepsy , 1998, Neurology.

[28]  A Drzezga,et al.  Reduction of Benzodiazepine Receptor Binding is Related to the Seizure Onset Zone in Extratemporal Focal Cortical Dysplasia , 2000, Epilepsia.

[29]  K. Herholz,et al.  “3D-Tool” - A Software System for Visualisation and Analysis of Coregistered Multimodality Volume Datasets of Individual Subjects , 1998, NeuroImage.

[30]  C. Elger,et al.  Surgical Treatment of Extratemporal Epilepsy: Clinical, Radiologic, and Histopathologic Findings in 60 Patients , 1996, Epilepsia.

[31]  U Pietrzyk,et al.  An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  K. Wienhard,et al.  MRI-Guided Flumazenil- and FDG-PET in Temporal Lobe Epilepsy , 1996, NeuroImage.

[33]  J. Mazziotta,et al.  Interictal metabolic anatomy of mesial temporal lobe epilepsy. , 1993, Archives of neurology.

[34]  Otto Muzik,et al.  [11ClFlumazenil PET in Patients with Epilepsy with Dual Pathology , 1999, Epilepsia.

[35]  R. Coleman,et al.  Temporal lobe hypometabolism on PET , 1993, Neurology.